MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 17, 2006; DOI: 10.1124/mol.105.019158


0026-895X/06/6904-1166-1173$20.00
Mol Pharmacol 69:1166-1173, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.019158v1
69/4/1166    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lazar, J.
Right arrow Articles by Lee, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lazar, J.
Right arrow Articles by Lee, J.
Original Article

Kinetics of Penetration Influence the Apparent Potency of Vanilloids on TRPV1

Jozsef Lazar, Derek C. Braun, Attila Tóth1, Yun Wang2, Larry V. Pearce, Vladimir A. Pavlyukovets, Peter M. Blumberg, Susan H. Garfield, Stephen Wincovitch, Hyun-Kyung Choi, and Jeewoo Lee

Laboratory of Cellular Carcinogenesis and Tumor Promotion (J.L., D.C.B., A.T., Y.W., L.V.P., V.A.P., P.M.B.) and Laboratory of Experimental Carcinogenesis (S.H.G., S.W.) National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Department of Biology, Gallaudet University, Washington DC (D.C.B.); and Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, South Korea (H.-K.C., J.L.)

Abstract

Evidence that the ligand binding site of TRPV1 lies on the inner face of the plasma membrane and that much of the TRPV1 itself is localized to internal membranes suggests that the rate of ligand entry into the cell may be an important determinant of the kinetics of ligand action. In this study, we synthesized a BODIPY TR-labeled fluorescent capsaicin analog (CHK-884) so that we could directly measure ligand entry. We report that CHK-884 penetrated only slowly into Chinese hamster ovary (CHO) cells expressing rat TRPV1, with a t1/2 of 30 ± 4 min, and localized in the endoplasmic reticulum and Golgi. Although CHK-884 was only weakly potent for TRPV1 binding (Ki = 6400 ± 230 nM), it was appreciably more potent when assayed by intracellular calcium imaging and was 3.2-fold more potent with a 1-h incubation time (37 nM) than with a 5-min incubation time. Olvanil, a highly lipophilic vanilloid, yielded an EC50 of 4.3 nM upon intracellular calcium imaging with an incubation time of 1 h, compared with an EC50 value of 29.5 nM for calcium imaging assayed at 5 min. Likewise, the antagonist 5-iodo-resiniferatoxin (5-iodo-RTX) displayed a Ki of 4.2 pM if incubated with CHO-TRPV1 cells for 2 h before addition of capsaicin compared with 1.5 nM if added simultaneously. We conclude that some vanilloids may have slow kinetics of uptake; this slow uptake may affect assessment of structure activity relations and may represent a significant factor for vanilloid drug design.


Received September 21, 2005; accepted January 13, 2006

Address correspondence to: Peter M. Blumberg, Molecular Mechanism of Tumor Promotion, Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, National Institutes of Health, Bldg. 37, Room 4048, 37 Convent Drive, MSC 4255, Bethesda, MD 20892-4255. E-mail: blumberp{at}dc37a.nci.nih.gov




This article has been cited by other articles:


Home page
Anesth. Analg.Home page
I. Kissin
Vanilloid-Induced Conduction Analgesia: Selective, Dose-Dependent, Long-Lasting, with a Low Level of Potential Neurotoxicity
Anesth. Analg., July 1, 2008; 107(1): 271 - 281.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
J. A. Matta, R. L. Miyares, and G. P. Ahern
TRPV1 is a novel target for omega-3 polyunsaturated fatty acids
J. Physiol., January 15, 2007; 578(2): 397 - 411.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics